Superworth

Vericel price to book ratio VCEL

Market value divided by the book value of the company's net assets, since 2013.

Today, Nov 2, 2026
5.6×
10-year median
7.9×
Against its 10-year history
11th
percentile: 0 is its lowest day, 100 its highest
10-year range
3.0× to 25.2×
Peer median
5.7×

Vericel's price to book ratio is 5.6× as of Nov 2, 2026.

That is below its ten-year median of 7.9×, lower than on 89% of days in the last ten years.

Over that time it ranged from 3.0× in Nov 2016 to 25.2× in Jun 2018.

The median for 8 biotech stocks of a similar size is 5.7×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far5.6×4.2×6.7×
20255.9×5.0×11.4×
202411.0×7.6×11.5×
20238.3×6.3×9.6×
20227.0×5.7×10.9×
202111.7×10.6×22.3×
202012.2×3.2×12.2×
20197.9×6.7×9.0×
20188.0×5.8×25.2×
201711.4×3.4×14.1×
20166.3×1.7×6.6×
20152.3×1.7×2.7×
20141.9×1.8×11.2×
20132.9×2.9×3.8×

Against its peers

Companies in Biotechnology nearest Vericel's size, closest first, today.

CompanyPrice to book ratio
VCELVericel5.6×
ADMAAdma Biologics6.1×
MGTXMeiraGTx4.2×
KRYSKrystal Biotech6.4×
RGENRepligen4.6×
TECHBIO-TECHNE5.4×
HALOHalozyme Therapeutics102×
NBIXNeurocrine Biosciences4.0×
EXELExelixis9.4×
Peer median5.7×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Vericel

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.